FDA asks Soligenix for new study after RTF; Navidea sells imaging agent for Alzheimer's
Earlier this year, the FDA handed a refusal-to-file letter to New Jersey-based rare disease biotech Soligenix for a drug to treat early-stage cutaneous T cell …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
